BACKGROUND: Eosinophils and lymphocytes are pathogenically important in allergic inflammation and sensitive to Fas-mediated apoptosis. Fas ligand (FasL) activity therefore should play a role in regulating the allergic immune response. We aimed to characterize the role of FasL expression in airway eosinophilia in Aspergillus fumigatus (Af)-induced sensitization and to determine whether FasL neutralization alters the inflammatory response. METHODS: Sensitized Balb/c mice were killed before (day 0) and 1, 7 and 10 days after a single intranasal challenge with Af. Animals received either neutralizing antibody to FasL (clone MFL4) or irrelevant hamster IgG via intraperitoneal injection on days -1 and 5. FasL expression, BAL and tissue inflammatory cell and cytokine profile, and apoptosis were assessed. RESULTS: Postchallenge FasL gene expression in BAL cells and TUNEL positivity in the airways coincided with the height of inflammatory cell influx on day 1, while soluble FasL protein was released on day 7, preceding resolution of the inflammatory changes. Although eosinophil numbers showed a negative correlation with soluble FasL levels in the airways, MBP(+) eosinophils remained TUNEL negative in the submucosal tissue, throughout the 10-day period after Af challenge. Systemic FasL neutralization significantly enhanced BAL and tissue eosinophil counts. This effect was associated with increased activation of T cells and release of IL-5, IL-9, and GM-CSF in the BAL fluid of mice, indicating an involvement of pro-eosinophilic survival pathways. CONCLUSIONS: FasL activity may play an active role in resolving eosinophilic inflammation through regulating T cells and pro-eosinophilic cytokine release during the allergic airway response.
BACKGROUND: Eosinophils and lymphocytes are pathogenically important in allergic inflammation and sensitive to Fas-mediated apoptosis. Fas ligand (FasL) activity therefore should play a role in regulating the allergic immune response. We aimed to characterize the role of FasL expression in airway eosinophilia in Aspergillus fumigatus (Af)-induced sensitization and to determine whether FasL neutralization alters the inflammatory response. METHODS: Sensitized Balb/c mice were killed before (day 0) and 1, 7 and 10 days after a single intranasal challenge with Af. Animals received either neutralizing antibody to FasL (clone MFL4) or irrelevant hamster IgG via intraperitoneal injection on days -1 and 5. FasL expression, BAL and tissue inflammatory cell and cytokine profile, and apoptosis were assessed. RESULTS: Postchallenge FasL gene expression in BAL cells and TUNEL positivity in the airways coincided with the height of inflammatory cell influx on day 1, while soluble FasL protein was released on day 7, preceding resolution of the inflammatory changes. Although eosinophil numbers showed a negative correlation with soluble FasL levels in the airways, MBP(+) eosinophils remained TUNEL negative in the submucosal tissue, throughout the 10-day period after Af challenge. Systemic FasL neutralization significantly enhanced BAL and tissue eosinophil counts. This effect was associated with increased activation of T cells and release of IL-5, IL-9, and GM-CSF in the BAL fluid of mice, indicating an involvement of pro-eosinophilic survival pathways. CONCLUSIONS:FasL activity may play an active role in resolving eosinophilic inflammation through regulating T cells and pro-eosinophilic cytokine release during the allergic airway response.
Authors: Amariliz Rivera; Grace Ro; Heather L Van Epps; Tyler Simpson; Ingrid Leiner; Derek B Sant'Angelo; Eric G Pamer Journal: Immunity Date: 2006-10-05 Impact factor: 31.745
Authors: L Formigli; L Papucci; A Tani; N Schiavone; A Tempestini; G E Orlandini; S Capaccioli; S Z Orlandini Journal: J Cell Physiol Date: 2000-01 Impact factor: 6.384
Authors: Jiankun Tong; Bryan S Clay; Caroline M Ferreira; Hozefa S Bandukwala; Tamson V Moore; Kelly M Blaine; Jesse W Williams; Lisa M Hoffman; Kimm J Hamann; Rebecca A Shilling; Joel V Weinstock; Anne I Sperling Journal: Am J Respir Cell Mol Biol Date: 2009-10-23 Impact factor: 6.914
Authors: Angela Haczku; Yang Cao; Geza Vass; Sonja Kierstein; Puneeta Nath; Elena N Atochina-Vasserman; Seth T Scanlon; Lily Li; Don E Griswold; K Fan Chung; Francis R Poulain; Samuel Hawgood; Michael F Beers; Erika C Crouch Journal: J Immunol Date: 2006-03-15 Impact factor: 5.422
Authors: Jeanne E Moorman; Rose Anne Rudd; Carol A Johnson; Michael King; Patrick Minor; Cathy Bailey; Marissa R Scalia; Lara J Akinbami Journal: MMWR Surveill Summ Date: 2007-10-19
Authors: S Kierstein; K Krytska; S Sharma; Y Amrani; M Salmon; R A Panettieri; J Zangrilli; A Haczku Journal: Allergy Date: 2008-04 Impact factor: 13.146
Authors: Jiankun Tong; Hozefa S Bandulwala; Bryan S Clay; Robert A Anders; Rebecca A Shilling; Diwakar D Balachandran; Bohao Chen; Joel V Weinstock; Julian Solway; Kimm J Hamann; Anne I Sperling Journal: J Exp Med Date: 2006-04-17 Impact factor: 14.307
Authors: Jacob Gibbens; Shauna-Kay Spencer; Lucia Solis; Teylor Bowles; Patrick B Kyle; Jamie L Szczepanski; John Polk Dumas; Reanna Robinson; Kedra Wallace Journal: Am J Physiol Regul Integr Comp Physiol Date: 2020-07-08 Impact factor: 3.619
Authors: C L Fang; L J Yin; S Sharma; S Kierstein; H F Wu; G Eid; A Haczku; C J Corrigan; S Ying Journal: Clin Exp Allergy Date: 2015-05 Impact factor: 5.018
Authors: Caroline M Ferreira; Jesse W Williams; Jiankun Tong; Crystal Rayon; Kelly M Blaine; Anne I Sperling Journal: Front Immunol Date: 2018-10-30 Impact factor: 7.561